SCHEMBL5779985

SCHEMBL5779985

CC(=O)Oc1ccccc1-c1nc2cc(Cl)ccc2c(=O)o1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELANE P08246 2/20 0.77
APEX1 P27695 1/20 0.63
PKM P14618 1/20 0.62
C1R P00736 4/20 0.54
ALDH1A1 P00352 4/20 0.50
MAPT P10636 3/20 0.50
LMNA P02545 1/20 0.50
KDM4E B2RXH2 2/20 0.49
KLK7 P49862 6/20 0.49
KLK14 Q9P0G3 6/20 0.49
KLK5 Q9Y337 6/20 0.49
CTSG P08311 5/20 0.49
PRSS1 P07477 1/20 0.49
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
POLB P06746 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
HPGD P15428 1/20 0.46
CTRC Q99895 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5921767 0.91 C1R (0.63) ELANEAPEX1PKMC1RALDH1A1
SCHEMBL5778170 0.87 PKM (0.64) ELANEAPEX1PKMC1RALDH1A1
SCHEMBL9984612 0.87 ELANE (1.00) ELANEAPEX1C1RALDH1A1MAPT
SCHEMBL5778141 0.85 C1R (0.73) ELANEPKMC1RALDH1A1MAPT
SCHEMBL5776241 0.83 ELANE (0.53) ELANEAPEX1PKMC1RALDH1A1
SCHEMBL17254727 0.81 ELANE (0.54) ELANEAPEX1PKMC1RALDH1A1
SCHEMBL5776060 0.81 ELANE (0.50) ELANEAPEX1PKMC1RALDH1A1
SCHEMBL5781524 0.80 C1R (0.55) ELANEPKMC1RALDH1A1MAPT
SCHEMBL17254720 0.80 CD74 (0.67) ELANEPKMC1RALDH1A1MAPT
SCHEMBL5921076 0.80 C1R (0.65) ELANEPKMC1RALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558260-A4 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMA INC (US) 2006-10-25 EP disclosed
US-20060052345-A1 Quinazolinone compounds as calcilytics NPS PHARMACEUTICALS, INC. (US) 2006-03-09 US disclosed
CN-1708306-A Quinazolinone compounds as calcilytics NPS PHARMA INC (US) 2005-12-14 CN disclosed
EP-1558260-A2 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2005-08-03 EP disclosed
WO-2004041755-A2 QUINAZOLINONE COMPOUNDS AS CALCILYTICS NPS PHARMACEUTICALS, INC. (US) 2004-05-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052345-A1 Quinazolinone compounds as calcilytics CALCR, CALCRL, CASR ELANE 3009/4885APEX1 2926/4885PKM 4408/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.